Neuro-Oncologic Veterinary Trial for the Clinical Transfer of Microbeam Radiation Therapy: Acute to Subacute Radiotolerance after Brain Tumor Irradiation in Pet Dogs

• Published in: Cancers 2024-08, Vol.16 (15), p.2701
• Main Authors: Eling, Laura, Kefs, Samy, Keshmiri, Sarvenaz, Balosso, Jacques, Calvet, Susan, Chamel, Gabriel, Drevon-Gaud, Renaud, Flandin, Isabelle, Gaudin, Maxime, Giraud, Lucile, Laissue, Jean Albert, Pellicioli, Paolo, Verry, Camille, Adam, Jean-François, Serduc, Raphaël
• Format: Article
• Language: English
• Subjects: Brain; Brain cancer; Brain tumors; Clinical trials; Dogs; Dosimetry; Evaluation; Glioma; Levetiracetam; Medical imaging; Medical prognosis; Patient safety; Patients; Positron emission tomography; Quality of life; Radiation; Radiation therapy; Radiotherapy; Seizures; Seizures (Medicine); Statistical analysis; Steroids
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers16152701

Synchrotron Microbeam Radiation Therapy (MRT) has repeatedly proven its superiority compared with conventional radiotherapy for glioma control in preclinical research. The clinical transfer phase of MRT has recently gained momentum; seven dogs with suspected glioma were treated under clinical conditions to determine the feasibility and safety of MRT. We administered a single fraction of 3D-conformal, image-guided MRT. Ultra-high-dose rate synchrotron X-ray microbeams (50 µm-wide, 400 µm-spaced) were delivered through five conformal irradiation ports. The PTV received ~25 Gy peak dose (within microbeams) per port, corresponding to a minimal cumulated valley dose (diffusing between microbeams) of 2.8 Gy. The dogs underwent clinical and MRI follow-up, and owner evaluations. One dog was lost to follow-up. Clinical exams of the remaining six dogs during the first 3 months did not indicate radiotoxicity induced by MRT. Quality of life improved from 7.3/10 [±0.7] to 8.9/10 [±0.3]. Tumor-induced seizure activity decreased significantly. A significant tumor volume reduction of 69% [±6%] was reached 3 months after MRT. Our study is the first neuro-oncologic veterinary trial of 3D-conformal Synchrotron MRT and reveals that MRT does not induce acute to subacute radiotoxicity in normal brain tissues. MRT improves quality of life and leads to remarkable tumor volume reduction despite low valley dose delivery. This trial is an essential step towards the forthcoming clinical application of MRT against deep-seated human brain tumors.